Christine Sekaggya‐wiltshire - Infectious Diseases

Author Information

Christine Sekaggya-Wiltshire is affiliated with the Infectious Diseases Institute at the College of Health Sciences, Makerere University, located in Kampala, Uganda. Her work primarily focuses on the field of infectious diseases, where she contributes to both clinical and research advancements.

Research Contributions

Christine Sekaggya-Wiltshire has made significant contributions to the field of infectious diseases, with a particular focus on tuberculosis, anticoagulation, and COVID-19 treatments in Uganda. Her research includes studies on chronic pulmonary aspergillosis in tuberculosis patients, psychological distress in patients on anticoagulation therapy, and the effectiveness of hydroxychloroquine for COVID-19 treatment. She also explores the implementation of TB preventive therapy and addresses challenges in anticoagulation practices in sub-Saharan Africa. Her work is pivotal in improving healthcare outcomes in low-income regions, especially regarding HIV and drug-resistant tuberculosis.

Aliases

Christine Sekaggya-Wiltshire is known by several aliases in academic publications, including C Sekaggya-wiltshire, C. Sekaggya-wiltshire, and Christine Sekaggya–wiltshire.

Publication and Citation Metrics

Metric	Value
Citation Count	494
H-index	12
Paper Count	69

Publications:

Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda.

DOI: 10.1111/myc.13444

Year: 2022

Prevalence and Factors Associated With Psychological Distress Among Patients on Anticoagulation With Warfarin at the Uganda Heart Institute, Mulago Hospital

DOI: 10.21203/rs.3.rs-1235049/v1

Year: 2022

Anticoagulation in sub‐Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin

DOI: 10.1111/bcp.14796

Year: 2021

Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.

DOI: 10.5588/ijtld.20.0100

Year: 2021

Improving anticoagulation in sub‐Saharan Africa: What are the challenges and how can we overcome them?

DOI: 10.1111/bcp.14768

Year: 2021

Chronic obstructive pulmonary disease prevalence and associated factors in an urban HIV clinic in a low income country

DOI: 10.1371/journal.pone.0256121

Year: 2021

Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

DOI: 10.1186/s12879-021-06897-9

Year: 2021

Safety and Efficacy of Hydroxychloroquine for Treatment of Non-Severe COVID-19 in Adults in Uganda: A Randomized Open Label Phase II Clinical Trial

DOI: 10.21203/RS.3.RS-506195/V1

Year: 2021

Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm

DOI: 10.1002/psp4.12740

Year: 2021

‘Out of sight, out of mind?’ A follow-up on HIV-infected patients with drug-resistant pulmonary tuberculosis in Uganda: A case series

DOI: 10.1177/2050313X211019790

Year: 2021

What Does the Future Hold for Personalized Medicine in Infectious Diseases?

Why Do Infectious Diseases Cause Fatigue?

How Do Fungi Infect Hosts?

How is ARDS Diagnosed?

How Can Ventilation Be Optimized in Public Spaces?

Can West Nile Virus be Prevented?

What is the Global Impact of Hepatitis B?

Why is Drug Resistance a Concern?

How Does Proteomics Help in Understanding Infectious Diseases?

What Role Does Sanitization Play in Infection Control?

Partnered Content Networks

Relevant Topics